Please assess the completion status of the following clinical trial:

Trial Title: Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Participant is an adult ≥18 years old at the time of consent~2. Participant with ABC (loco regionally recurrent or metastatic) not amenable to curative therapy.~3. Participant with a histologically and/or cytologically confirmed diagnosis of ER-positive and/or PR-positive breast cancer by local laboratory.~4. Participant with a confirmed HER2-negative ABC.~5. Participant with a pathology report confirming PIK3CA mutant status by a certified laboratory using a validated PIK3CA mutation assay (from either tissue or blood).~6. Participant was willing to operate a smartphone compatible with the software of the medical device and willing to manage applications~7. Participant was willing to use the telemedicine platform and to follow the remote participant monitoring procedure.~Key Exclusion Criteria:~1. Participant had received prior treatment with any PI3K, mTOR or AKT inhibitor.~2. Participant with known hypersensitivity to alpelisib or fulvestrant, or to any of the excipients of alpelisib or fulvestrant.~3. Participant participated in a prior investigational study within 30 days prior to the start of trial treatment or within 5 half-lives of the trial treatment, whichever was longer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Alpelisib + fulvestrant (Type: EXPERIMENTAL): Participants were administered alpelisib at a daily dose of 300 mg for 12 cycles of 28 days and fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and Day 1 of each subsequent cycle up to Cycle 12. Pre-menopausal women also received goserelin at a dose of 3.6 mg on Day 1 of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).